Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT) (BESTFIT)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Tonix Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01903265
First received: July 12, 2013
Last updated: November 5, 2015
Last verified: November 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2015
  Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)